Procept BioRobotics Corporation (PRCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer
PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.
Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
The FDA's approval of Procept's Hrydos system is a meaningful catalyst to the investment debate. Investors have added ~$5/share in market value since the announcement. PRCT's Q2 '24 numbers were equally as strong and exhibited an extensive runway of growth ahead in my view.
PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance
PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.
PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
Surgical robotics company PROCEPT BioRobotics Co. NASDAQ: PRCT developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia (BPH) among aging men. The company went public during the special purpose acquisition company (SPAC) mania in 2021.
PROCEPT BioRobotics Corporation (PRCT) Q2 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive VP, Chief Commercial Officer Kevin Waters - Executive VP, Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Matthew O'Brien - Piper Sandler Richard Newitter - Truist Brandon Vasquez - William Blair Joshua Jennings - TD Cowen Dino Weinstock - Wells Fargo Ryan Zimmerman - BTIG Operator Good afternoon and welcome to PROCEPT BioRobotics Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.56 per share a year ago.
